CN103330692B - 提高稳定性的辛伐他汀片剂 - Google Patents
提高稳定性的辛伐他汀片剂 Download PDFInfo
- Publication number
- CN103330692B CN103330692B CN201310238166.2A CN201310238166A CN103330692B CN 103330692 B CN103330692 B CN 103330692B CN 201310238166 A CN201310238166 A CN 201310238166A CN 103330692 B CN103330692 B CN 103330692B
- Authority
- CN
- China
- Prior art keywords
- simvastatin
- tablet
- adjuvant
- stability according
- raising stability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 229960002855 simvastatin Drugs 0.000 title claims abstract description 55
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 12
- 229920002472 Starch Polymers 0.000 claims abstract description 11
- 239000008107 starch Substances 0.000 claims abstract description 11
- 235000019698 starch Nutrition 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 6
- 239000008101 lactose Substances 0.000 claims abstract description 6
- 239000011734 sodium Substances 0.000 claims abstract description 6
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 6
- 239000002671 adjuvant Substances 0.000 claims description 20
- 239000011812 mixed powder Substances 0.000 claims description 15
- 229960003943 hypromellose Drugs 0.000 claims description 11
- 238000007791 dehumidification Methods 0.000 claims description 7
- 239000002274 desiccant Substances 0.000 claims description 7
- 229950005770 hyprolose Drugs 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 238000004090 dissolution Methods 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 235000015424 sodium Nutrition 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- PNAMDJVUJCJOIX-IUNFJCKHSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-IUNFJCKHSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940074790 simvastatin and ezetimibe Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310238166.2A CN103330692B (zh) | 2013-06-17 | 2013-06-17 | 提高稳定性的辛伐他汀片剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310238166.2A CN103330692B (zh) | 2013-06-17 | 2013-06-17 | 提高稳定性的辛伐他汀片剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103330692A CN103330692A (zh) | 2013-10-02 |
CN103330692B true CN103330692B (zh) | 2015-04-22 |
Family
ID=49238944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310238166.2A Active CN103330692B (zh) | 2013-06-17 | 2013-06-17 | 提高稳定性的辛伐他汀片剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103330692B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105106198B (zh) * | 2015-09-18 | 2018-02-23 | 康普药业股份有限公司 | 一种高稳定性的辛伐他汀片及其制备方法 |
CN111481514B (zh) * | 2019-01-25 | 2023-01-10 | 鲁南制药集团股份有限公司 | 一种治疗高血脂的片剂及其制备方法 |
CN110025586B (zh) * | 2019-04-16 | 2021-06-29 | 天方药业有限公司 | 辛伐他汀片剂的制备方法及其所得辛伐他汀片剂 |
CN113797173B (zh) * | 2021-10-31 | 2023-03-17 | 海南海灵化学制药有限公司 | 一种高稳定性的辛伐他汀片及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1977841A (zh) * | 2005-12-08 | 2007-06-13 | 上海信谊万象药业股份有限公司 | 辛伐他汀片剂的制备方法 |
CN102091050A (zh) * | 2011-01-31 | 2011-06-15 | 重庆科瑞制药有限责任公司 | 一种稳定的辛伐他汀口服片剂及其制备方法 |
-
2013
- 2013-06-17 CN CN201310238166.2A patent/CN103330692B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1977841A (zh) * | 2005-12-08 | 2007-06-13 | 上海信谊万象药业股份有限公司 | 辛伐他汀片剂的制备方法 |
CN102091050A (zh) * | 2011-01-31 | 2011-06-15 | 重庆科瑞制药有限责任公司 | 一种稳定的辛伐他汀口服片剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103330692A (zh) | 2013-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103330692B (zh) | 提高稳定性的辛伐他汀片剂 | |
CN103494785B (zh) | 一种孟鲁司特钠咀嚼片及其制备方法 | |
CN104523640B (zh) | 一种替格瑞洛片及其制备方法 | |
CN102988993B (zh) | 复方对乙酰氨基酚片主要辅料的筛选和组成及其制备方法 | |
CN103127025B (zh) | 消旋2-(α-羟基戊基)苯甲酸盐片的制备方法 | |
CN100341522C (zh) | 银杏叶缓释片及其制备方法 | |
CN114288257B (zh) | 一种马来酸氟伏沙明片剂及其制备方法 | |
CN103099789A (zh) | 一种维生素c颗粒的制备方法 | |
CN103720660A (zh) | 一种核黄素颗粒及其制备方法 | |
CN106963938A (zh) | 一种马来酸依那普利叶酸的药物组合物及其制备方法 | |
CN104337782A (zh) | 一种甲磺酸伊马替尼片剂 | |
CN102349915A (zh) | 一种氨酚咖敏维c制剂及其制备方法 | |
CN103330691B (zh) | 提高硬度的辛伐他汀片剂及其制备方法 | |
CN103330693B (zh) | 提高崩解性的辛伐他汀组合物及其制备方法 | |
CN109953960A (zh) | 一种苯磺酸氨氯地平片的制备方法 | |
CN102038685A (zh) | 具有改善的口服吸收性的布南色林药物组合物 | |
CN103655507A (zh) | 盐酸莫西沙星片剂及其制备方法 | |
CN103405394A (zh) | 一种酒石酸美托洛尔缓释片及其制备方法 | |
CN103735544A (zh) | 一种维达列汀/盐酸二甲双胍复方制剂的制备工艺 | |
CN105106144A (zh) | 一种盐酸西那卡塞固体分散体片剂及其制备工艺 | |
CN102988372A (zh) | 复方阿司匹林片主要辅料的筛选和组成及其制备方法 | |
CN102366412A (zh) | 一种托伐普坦片剂的制备方法 | |
CN104983705A (zh) | 硫酸普拉睾酮钠缓释片及其制备方法 | |
CN103142500B (zh) | 一种依托泊苷缓释颗粒 | |
CN103948562A (zh) | 一种地氯雷他定胶囊及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Fangfang Inventor before: Chen Jiyuan Inventor before: Shen Shan |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170516 Address after: 030699 Yuci Industrial Park, Yuci District, Shanxi, Jinzhong Patentee after: Shanxi Xinyu Pharmaceutical Co., Ltd. Address before: 610000 Chengdu high tech West Road, Sichuan, No. 18 Patentee before: Sichuan Pharmaceutical Inc. |
|
TR01 | Transfer of patent right | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Fangfang Inventor after: Li Zhiguo Inventor before: Liu Fangfang |
|
CB03 | Change of inventor or designer information | ||
CP01 | Change in the name or title of a patent holder |
Address after: 030600 Yuci Industrial Park, Yuci District, Jinzhong City, Shanxi Province Patentee after: Shanxi Xinyu Pharmaceutical Co.,Ltd. Address before: 030600 Yuci Industrial Park, Yuci District, Jinzhong City, Shanxi Province Patentee before: SHANXI XINYU PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |